Patents by Inventor Gregory D. Plowman

Gregory D. Plowman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • KRAS VARIANT MRNA MOLECULES
    Publication number: 20220340641
    Abstract: The present invention provides an mRNA molecule encoding at least one KRAS variant peptide. Further, the invention provides a pharmaceutical composition and kit comprising the mRNA molecule. The mRNA molecule, pharmaceutical composition and kit are useful for treating cancer.
    Type: Application
    Filed: December 6, 2019
    Publication date: October 27, 2022
    Applicant: CureVac AG
    Inventors: Amit AGGARWAL, Katja FIEDLER, Ulrike GNAD-VOGT, Regina HEIDENREICH, Mythili KONERU, Gregory D. PLOWMAN
  • Checkpoint inhibitor bispecific antibodies
    Patent number: 11203640
    Abstract: The present invention relates to antibodies that are heterodimeric and bind human PD-L1 and human PD-1, and may be useful for treating cancer alone and in combination with chemotherapy and other cancer therapeutics.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: December 21, 2021
    Assignees: Eli Lilly and Company, Zymeworks Inc.
    Inventors: Michael Dewain Kalos, Yiwen Li, Dale Lincoln Ludwig, Yang Shen, Igor Edmondo Paolo D'Angelo, Gregory D Plowman
  • Checkpoint Inhibitor Bispecific Antibodies
    Publication number: 20190010232
    Abstract: The present invention relates to antibodies that are heterodimeric and bind human PD-L1 and human PD-1, and may be useful for treating cancer alone and in combination with chemotherapy and other cancer therapeutics.
    Type: Application
    Filed: July 9, 2018
    Publication date: January 10, 2019
    Inventors: Michael Dewain Kalos, Yiwen Li, Dale Lincoln Ludwig, Yang Shen, Igor Edmondo Paolo D'Angelo, Gregory D Plowman
  • Compounds to fibroblast growth factor receptor-3 (FGFR3) and methods of treatment
    Patent number: 9375488
    Abstract: The invention provides conjugates that consist of a drug moiety agent and a cell binding agent that target human fibroblast growth factor receptor 3 (FGFR3). These conjugates have therapeutic use as they are designed and tailored to target a specific cell population and deliver a powerful cytotoxin inside the cell. The conjugate of the present invention has significant advantages over other conjugates known in the art by providing a targeted tumor therapy as well as bystander activity to neighboring cells in an important oncology receptor that is only moderately expressed.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: June 28, 2016
    Assignees: ImClone, LLC, ImmunoGen, Inc.
    Inventors: Paul J. Balderes, Scott W. Eastman, Hans K. Erickson, Dale L. Ludwig, Christopher M. Moxham, Gregory D. Plowman, Alan C. Rigby
  • Antibodies
    Patent number: 9284376
    Abstract: The present invention relates to the use of VEGF antagonists and a novel anti-?5?1 antibody for treating cancer and inhibiting angiogenesis and/or vascular permeability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to compositions and kits comprising novel anti-?5?1 antibodies and methods of making and using them.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: March 15, 2016
    Assignee: Genentech, Inc.
    Inventors: Wei-Ching Liang, Gregory D. Plowman, Yan Wu, Weilan Ye
  • NOVEL ANTI- ALPHA5 BETA1 ANTIBODIES AND USES THEREOF
    Publication number: 20150203581
    Abstract: The present invention provides new anti-?5?1 antibodies, compositions and kits comprising the antibodies, and methods of making and using the antibodies.
    Type: Application
    Filed: January 9, 2015
    Publication date: July 23, 2015
    Inventors: Wei-Ching LIANG, Gregory D. PLOWMAN, Yan WU, Weilan YE
  • COMPOUNDS TO FIBROBLAST GROWTH FACTOR RECEPTOR-3 (FGFR3) AND METHODS OF TREATMENT
    Publication number: 20150165067
    Abstract: The invention provides conjugates that consist of a drug moiety agent and a cell binding agent that target human fibroblast growth factor receptor 3 (FGFR3). These conjugates have therapeutic use as they are designed and tailored to target a specific cell population and deliver a powerful cytotoxin inside the cell. The conjugate of the present invention has significant advantages over other conjugates known in the art by providing a targeted tumor therapy as well as bystander activity to neighboring cells in an important oncology receptor that is only moderately expressed.
    Type: Application
    Filed: December 11, 2014
    Publication date: June 18, 2015
    Applicants: IMCLONE LLC, IMMUNOGEN, INC.
    Inventors: Paul J. BALDERES, Scott W. EASTMAN, Hans K. ERICKSON, Dale L. LUDWIG, Christopher M. MOXHAM, Gregory D. PLOWMAN, Alan C. RIGBY
  • Anti-?5?1 antibodies and uses thereof
    Patent number: 8962275
    Abstract: The present invention provides new anti-?5?1 antibodies, compositions and kits comprising the antibodies, and methods of making and using the antibodies.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: February 24, 2015
    Assignee: Genentech, Inc.
    Inventors: Wei-Ching Liang, Gregory D. Plowman, Yan Wu, Weilan Ye
  • BLOOD PLASMA BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES FOR TREATMENT OF BREAST CANCER
    Publication number: 20140341893
    Abstract: The present invention provides methods for improving the treatment effect of a chemotherapy regimen of a patient suffering from HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer, by adding bevacizumab (Avastin®) to a chemotherapy regimen by determining the expression level, in particular the blood plasma expression level, of VEGFA and/or VEGFR2 relative to control levels of patients diagnosed with HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer. The present invention also provides for methods for assessing the sensitivity or responsiveness of a patient to bevacizumab (Avastin®) in combination with a chemotherapy regimen, by determining the expression level, in particular the blood plasma expression level, of VEGFA and/or VEGFR2 relative to control levels in patients diagnosed with HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer.
    Type: Application
    Filed: May 28, 2014
    Publication date: November 20, 2014
    Applicant: Genentech, Inc.
    Inventors: Herbert Andres, Sanne Lysbet de Haas, Rebecca Elliott, Johann Karl, Yu-Ju Gloria Meng, Gregory D. Plowman, Stefan Scherer, Norbert Wild
  • Antibodies
    Patent number: 8840887
    Abstract: The present invention relates to the use of VEGF antagonists and a novel anti-?5?1 antibody for treating cancer and inhibiting angiogenesis and/or vascular permeability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to compositions and kits comprising novel anti-?5?1 antibodies and methods of making and using them.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: September 23, 2014
    Assignee: Genentech, Inc.
    Inventors: Wei-Ching Liang, Gregory D. Plowman, Yan Wu, Weilan Ye
  • SCDs as modifiers of the p53 pathway and methods of use
    Patent number: 8771942
    Abstract: Human SCD genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of SCD are provided.
    Type: Grant
    Filed: February 26, 2010
    Date of Patent: July 8, 2014
    Assignee: Exelixis, Inc.
    Inventors: Marcia Belvin, Helen Francis-Lang, Lori Friedman, Gregory D. Plowman, Timothy S. Heuer
  • METHOD TO IDENTIFY A PATEINT WITH AN INCREASED LIKELIHOOD OF RESPONDING TO AN ANTI-CANCER THERAPY
    Publication number: 20140056875
    Abstract: The invention provides methods for identifying patient who may benefit from treatment with an anti-cancer therapy comprising a VEGF antagonist. The invention also provides methods for monitoring a patients' response to the anti-cancer therapy. The invention also provides kits and articles of manufacture for use in the methods.
    Type: Application
    Filed: March 13, 2013
    Publication date: February 27, 2014
    Applicants: GENENTECH. INC., HOFFMANN-LA ROCHE INC.
    Inventors: Herbert Andres, Sanne Lysbet De Haas, Rebecca Elliott, Johann Karl, Yu-Ju Gloria Meng, Gregory D. Plowman, Stefan Scherer, Norbert Wild
  • METHOD TO IDENTIFY A PATEINT WITH AN INCREASED LIKELIHOOD OF RESPONDING TO AN ANTI-CANCER THERAPY
    Publication number: 20140056874
    Abstract: The invention provides methods for identifying patient who may benefit from treatment with an anti-cancer therapy comprising a VEGF antagonist. The invention also provides methods for monitoring a patients' response to the anti-cancer therapy. The invention also provides kits and articles of manufacture for use in the methods.
    Type: Application
    Filed: March 13, 2013
    Publication date: February 27, 2014
    Applicants: GENENTECH. INC., HOFFMANN-LA ROCHE INC.
    Inventors: Herbert Andres, Sanne Lysbet De Haas, Rebecca Elliott, Johann Karl, Yu-Ju Gloria Meng, Gregory D. Plowman, Stefan Scherer, Norbert Wild
  • METHOD TO IDENTIFY A PATIENT WITH AN INCREASED LIKELIHOOD OF RESPONDING TO AN ANTI-CANCER THERAPY
    Publication number: 20140023639
    Abstract: The invention provides methods for identifying patient who may benefit from treatment with an anti-cancer therapy comprising a VEGF antagonist. The invention also provides methods for monitoring a patients' response to the anti-cancer therapy. The invention also provides kits and articles of manufacture for use in the methods.
    Type: Application
    Filed: March 13, 2013
    Publication date: January 23, 2014
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Herbert Andres, Sanne Lysbet De Haas, Rebecca Elliott, Johann Karl, Yu-Ju Gloria Meng, Gregory D. Plowman, Stefan Scherer, Norbert Wild
  • COMBINATORIAL THERAPY
    Publication number: 20140004038
    Abstract: The present invention relates to the use of VEGF antagonists and alpha5beta1 antagonists for treating cancer and inhibiting angiogenesis and/or vascular permeability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to use of a VEGFR agonists and alpha5beta1 agonists to promote angiogenesis and vascular permeability. The present invention also relates to new anti-alpha5beta1 antibodies, compositions and kits comprising them and methods of making and using them.
    Type: Application
    Filed: December 7, 2012
    Publication date: January 2, 2014
    Applicant: Genentech, Inc.
    Inventors: Anan Chuntharapai, Gregory D. Plowman, Marc Tessier-Lavigne, Yan Wu, Weilan Ye
  • Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
    Publication number: 20130344059
    Abstract: The invention provides methods for identifying patient who may benefit from treatment with an anti-cancer therapy comprising a VEGF antagonist. The invention also provides methods for monitoring a patients' response to the anti-cancer therapy. The invention also provides kits and articles of manufacture for use in the methods.
    Type: Application
    Filed: January 17, 2013
    Publication date: December 26, 2013
    Applicants: GENENTECH. INC., HOFFMANN-LA ROCHE INC.
    Inventors: Herbert Andres, Sanne Lysbet De Haas, Rebecca Elliott, Johann Karl, Yu-Ju Gloria Meng, Gregory D. Plowman, Stefan Scherer, Norbert Wild
  • NOVEL ANTI- ALPHA5BETA1 ANTIBODIES AND USES THEREOF
    Publication number: 20130095096
    Abstract: The present invention provides new anti-?5?1 antibodies, compositions and kits comprising the antibodies, and methods of making and using the antibodies.
    Type: Application
    Filed: December 22, 2011
    Publication date: April 18, 2013
    Applicant: Genentech, Inc.
    Inventors: Wei-Ching Liang, Gregory D. Plowman, Yan Wu, Weilan Ye
  • Anti-alpha5/beta1 antibody
    Patent number: 8350010
    Abstract: The present invention relates to the use of VEGF antagonists and alpha5beta1 antagonists for treating cancer and inhibiting angiogenesis and/or vascular permeability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to use of a VEGFR agonists and alpha5beta1 agonists to promote angiogenesis and vascular permeability. The present invention also relates to new anti-alpha5beta1 antibodies, compositions and kits comprising them and methods of making and using them.
    Type: Grant
    Filed: June 28, 2011
    Date of Patent: January 8, 2013
    Assignee: Genentech, Inc.
    Inventors: Anan Chuntharapai, Gregory D. Plowman, Marc Tessier-Lavigne, Yan Wu, Weilan Ye
  • MAP3Ks as modifiers of the p53 pathway and methods of use
    Patent number: 8268548
    Abstract: Human MAP3K genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of MAP3K are provided.
    Type: Grant
    Filed: April 18, 2007
    Date of Patent: September 18, 2012
    Assignee: Exelixis, Inc.
    Inventors: Lori Friedman, Gregory D. Plowman, Marcia Belvin, Helen Francis-Lang, Danix Li, Roel P. Funke
  • COMBINATORIAL THERAPY
    Publication number: 20120195908
    Abstract: The present invention relates to the use of VEGF antagonists and alpha5beta1 antagonists for treating cancer and inhibiting angiogenesis and/or vascular permeability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to use of a VEGFR agonists and alpha5beta1 agonists to promote angiogenesis and vascular permeability. The present invention also relates to new anti-alpha5beta1 antibodies, compositions and kits comprising them and methods of making and using them.
    Type: Application
    Filed: June 28, 2011
    Publication date: August 2, 2012
    Inventors: Anan Chuntharapai, Gregory D. Plowman, Marc Tessier-Lavigne, Yan Wu, Weilan Ye